DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company’s lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company’s investors include Morningside Ventures and Mercury Fund.
Company Details
- Founded
- 2005
- Address
- 10355 Science Center Drive,
- Phone
- 7137156826
- in****@****rix.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- dnatrix.com
- HQ
- San Diego, CA
Dnatrix Questions
Dnatrix's helpline number is 7137156826
Dnatrix's website is dnatrix.com
Dnatrix's LinkedIn profile is https://www.linkedin.com/company/dnatrix
Dnatrix's industry is
Biotechnology Research
Dnatrix's top competitors are
Roche,
Mpm Capital,
Bellicum Pharmaceuticals, Inc.,
Coya Therapeutics, Inc.,
Allera Health Products,
Replay,
Tvardi Therapeutics,
Omniscience,
Immatics,
Milab Scientific.
Dnatrix's support email address is info@dnatrix.com
Dnatrix's categories are Biotechnology Research
Dnatrix's founding year is 2005
